Sanofi SA · EURONEXT:SAN
Sanofi SA — CLSA Investors Forum 2014
27 slides from Sanofi SA's conference presentation, Sep 17, 2014
Slide 1: CLSA Investors Forum 2014
CSLA Investors Forum 2014 Jean-Marie Arnaud, Vice President, South East Asia & IndoChina, Global Operations Hong Kong, September 17, 2014
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their under
Slide 3: Agenda
Agenda Sanofi Highlights to Date Emerging Markets - Strong Contribution from Asia Region The Opportunity with Sanofi 3
Slide 4: Sanofi is a Global Integrated Healthcare Company
Sanofi is a Global Integrated Healthcare Company present in A diversified more than offer 110,000 100 of medicines, vaccines and innovative (1 Employees ) countries therapeutic solutions €33bn 112 industrial in sales Sites in in 2013 41 countries • We are a global integrated healthcare company engag
Slide 5: Executing a Successful Strategy
Executing a Successful Strategy Grow a global healthcare leader 1 with synergistic platforms 2 Bring innovative products to market Deliver sustainable long-term growth and maximize Seize value-enhancing growth 3 shareholder returns opportunities Adapt structure for future 4 challenges and opportunit
Slide 6: Sanofi Delivered Solid Results in Q2 2014
Sanofi Delivered Solid Results in Q2 2014 (1) ● Net sales up +6.4% at CER and Business EPS up +13.4% at CER Solid financial ● Free Cash Flow up +33% in H1 2014 1 performance ● (2) (3) €3.7bn dividend payment and €1.1bn share buyback Strong ● 76.3% of Group sales performance 2 ● Solid execution in Em
Slide 7: Solid Q2 2014 Financial Performance Reflects Consistent Execution of our Growth Strategy
Solid Q2 2014 Financial Performance Reflects Consistent Execution of our Growth Strategy Net Sales(1) Business EPS(1) +€515m -€443m -€0.10 +€0.15 (2) €8,075m €1.17 €8,003m €1.12 +6.4% +13.4% at CER(1) at CER(1) (2) Q2 2013 Incremental FX Impact Q2 2014 Q2 2013 Incremental FX Impact Q2 2014 Sales at
Slide 8: Growth Platforms Grew +14.5% in Q2 2014 Reaching 76.3% of Sales
Growth Platforms Grew +14.5%(1) in Q2 2014 Reaching 76.3% of Sales Q2 2014 H1 2014 Growth at CER Growth at CER Emerging Markets(2) €2,855m +16.5% +11.0% Diabetes Solutions €1,788m +16.2% +14.7% Consumer Healthcare(3) €816m +9.2% +9.3% Vaccines €718m -0.4% -4.2% -2.2% -4.2% Genzyme(4) €643m +29.1% +2
Slide 9: Growth Platforms Show Consistent Strong Performance
Growth Platforms Show Consistent Strong Performance Demonstrating the Value of our Business Model Quarterly Sales Growth from Growth Platforms(1) +11.5% (2) +10.7% +10% +10.0% at CER +8.6% +7.6% +7.9% (2) +6.4% +6.2% +5.7% +5.5% +5% at CER Q1 2012 Q2 2012 Q3 2012 Q4 2012 Q1 2013 Q2 2013 Q3 2013 Q4 2
Slide 10: Agenda
Agenda Sanofi Highlights to Date Emerging Markets - Strong Contribution from Asia Region The Opportunity with Sanofi 10
Slide 11: Solid Sales Performance in Emerging Markets in H1 2014
Solid Sales Performance in Emerging Markets in H1 2014 as Operational Issues from 2013 Have Been Addressed H1 2014 Geographic Sales Mix Emerging Markets Total Sales by Region -7.4% 10.0% -1.5% 24.5% (1) 34.2% +11.0% 31.3% +8.5% (2) Growth at CER -0.7% +4.7% +5.4% +14.6% excluding Brazil Generics (1)
Slide 12: Poised for Continued Strong Growth in the 'Asia Region'
Poised for Continued Strong Growth in the ‘Asia Region’ Perimeter of ‘Asia Region’ at Sanofi ● Regional headquarters in Shanghai ● Strategic hub in Singapore ● 10 country affiliates ● >12,000 employees in the ‘Asia China region’ Hong Taiwan ● Growing presence in Consumer Kong Healthc
Slide 13: Sanofi in China - Well Poised to Seize the Opportunities in the Chinese Healthcare Market
Sanofi in China - Well Poised to Seize the Opportunities in the Chinese Healthcare Market Regional offices Production Sites Regional R&D R&D center A Fully Integrated Presence ● >8,500 Employees Urumqi ● >5,000 Sales force Shenyang Beijing Tangshan ● 11 Regional Offices Tianjin 11 ● Regional R&D Pla
Slide 14: Sanofi in China – A Strong and Growing Contributor to Our Leadership Position
Sanofi in China – A Strong and Growing Contributor to Our Leadership Position in Emerging Markets Ranked #4 in China(1) Sanofi Sales in China(2) 1 PFIZER €1,471m 2 ASTRAZENECA 3 SHANDONG QILU FTY +33% 4 5 BAYER 6 JS. YANGZIJIANG FTY 7 ROCHE €347m 8 KE LUN 9 NOVARTIS 10 JS.L.Y.G. HENGRUI 2008 2009 20
Slide 15: Progressively Developing Our Growth Platforms in China
Progressively Developing Our Growth Platforms in China Breakdown of Sanofi Sales in China(1) by Business(2) 2007 2013 Pharmaceuticals Vaccines Diabetes 72% Genzyme Consumer Healthcare Animal Health/Merial Total Sales €273m Total Sales €1,471m (1) Mainland China (2) Illustrative 15
Slide 16: South East Asia Represents a Major Growth Opportunity
South East Asia Represents a Major Growth Opportunity Heathcare Expenditure as a % of GDP ● GDP growth in most SEA countries still low in most fast growing SEA economies higher than in developed markets Healthcare expenditure ● Diverse political systems and GDP growth in %(1) as % of GDP(2) economic
Slide 17: Positive Outlook for the Pharmaceutical Market in South East Asia
Positive Outlook for the Pharmaceutical Market in South East Asia South East Asia Pharmaceutical Market(1) ● Population of >500m people In € billion(2) 17.2 CAGR ● South East Asia Pharmaceutical +9% ‘13-’17 market estimated to be ~€12bn(1) ● Growth of +9%, 2013 – 2017 CAGR 1.7 Cambodia 12.1 ● Fastes
Slide 18: Sanofi is an Established Leader in South East Asia
Sanofi is an Established Leader in South East Asia Top 10 Pharmaceutical Companies in South East Asia(1) Sales in € million (2013) ● A broad portfolio to address local Pfizer market needs and to capture growth opportunities Unilab ● Investment focus on priority markets GSK ● Improved access through
Slide 19: Agenda
Agenda Sanofi Highlights to Date Emerging Markets - Strong Contribution from Asia Region The Opportunity with Sanofi 19
Slide 20: Three New Medicines Under Regulatory Review
Three New Medicines Under Regulatory Review with the Potential to Meaningfully Improve Patient Lives ● Filed in the U.S. and EU ● sBLA resubmission ● FDA approval granted in in Q2 2014 and recently accepted for review August 2014 in Japan by FDA in May 2014 ● EU regulatory decision ● Regulatory deci
Slide 21: Alirocumab Illustrates Sanofi's Focus on Gearing Up to Successful Launches of Biologics
Alirocumab Illustrates Sanofi’s Focus on Gearing Up to Successful Launches of Biologics 21
Slide 22: PCSK9 Inhibitors Have the Potential to Improve LDL-C Management
PCSK9 Inhibitors Have the Potential to Improve LDL-C Management of High Cardiovascular (CV) Risk Patients ● High LDL-C and CV diseases remain an area of high unmet medical need ● Large and comprehensive Phase 3 ODYSSEY clinical program designed to assess the safety and efficacy of alirocumab in pati
Slide 23: First-in-Class Dengue Vaccine Met Primary Endpoint in Phase III Trials
First-in-Class Dengue Vaccine Met Primary Endpoint in 2 Phase III Trials in Asia and Latin America The Global Disease Burden of Dengue(1) Sanofi’s Dengue vaccine candidate Aedes aegypti moscito Two successfully Study in Study in completed Asia LatAm Phase III studies(2) Number of 10,275 20,875 parti
Slide 24: Strong Late Stage Pipeline of Biologics Demonstrates the Shift towards Innovative Products
Strong Late Stage Pipeline of Biologics Demonstrates the Shift of our Portfolio towards Innovative Products Sarilumab Dengue Vaccine Atopic Dermatitis Rheumatoid Arthritis ● First Phase III study in Asia ● Strong Phase IIa data ● Detailed data from positive published in The Lancet published in the N
Slide 25: Two New Collaborations Signed in Q2 2014
Two New Collaborations Signed in Q2 2014 Strengthening our CHC and Diabetes Growth Platforms ● Licensing agreement with Lilly ● Opportunity to switch Cialis® from Rx to OTC in the U.S., Europe, Canada and Australia(1) ● Ambition to transform how this important medicine for erectile dysfunction (ED)
Slide 26: Solid H1 Performance Reflects Consistent Execution of our Growth Strategy
Solid H1 Performance Reflects Consistent Execution of our Growth Strategy Over 75% of sales now being generated by Growth Platforms Business EPS guidance for 2014 adjusted slightly upwards Late stage pipeline moving to launch execution Expected new medicine launches to further redefine Sanofi as a b
Slide 27: The Opportunity with Sanofi
The Opportunity with Sanofi Sanofi has transformed into a company positioned for sustainable growth through its Growth Platforms(1) and has a robust late-stage pipeline of new biologics (1) Growth Platforms include Emerging Markets, Diabetes Solutions, Vaccines, Consumer Healthcare, Animal Health, G